中国临床药理学与治疗学2026，Vol.31Issue(3)：428-432,5.DOI:10.12092/j.issn.1009-2501.2026.03.015
新型抗精神病药KarXT
New antipsychotic drug KarXT
摘要
Abstract
At present,antipsychotic drugs mainly act on dopamine receptors,but the improvement of negative symptoms and cognitive symptoms is lim-ited.There are extrapyramidal adverse reactions,metabolic syndrome,endocrine disorders and oth-er adverse reactions,which some patients can not tolerate.KarXT(trade name Cobenfy),a novel an-tipsychotic drug approved by the FDA for the treat-ment of schizophrenia in adults,acts on M1 and M4 muscarinic acetylcholine receptors(mAChR).The results of current clinical trials have shown that KarXT can improve the positive symptoms,nega-tive symptoms and cognitive impairment of schizophrenia,and the adverse reactions are main-ly gastrointestinal symptoms.This article reviews the latest literature on the pharmacological mecha-nism,pharmacokinetics,clinical evaluation,and safety of KarXT.关键词
抗精神病药/临床试验/药物评价/药物相关性副作用和不良反应/认知损害Key words
antipsychotic agents/clinical trial/drug evaluation/drug-related side effects and ad-verse reactions/cognitive dysfunction分类
医药卫生引用本文复制引用
刘鑫,刘小琳,周亚楠,翟金国..新型抗精神病药KarXT[J].中国临床药理学与治疗学,2026,31(3):428-432,5.基金项目
山东省自然科学基金项目(ZR2017LH036) （ZR2017LH036）
济宁市重点研发计划项目(2024YXNS200) （2024YXNS200）
